Other Pharmerging Markets
Our API Other Pharmerging Markets Portfolio** consists of the following: Please Note - PhM DMF are shared on basis of customer request
| Therapeutic Category | Name of API |
|---|---|
| Anti-cancer | Anastrozole |
| Azacitidine | |
| Afatinib dimaleate | |
| Bicalutamide | |
| Belinostat | |
| Bortezomib | |
| Busulfan | |
| Cabazitaxel | |
| Carboplatin | |
| Carfilzomib | |
| Decitabine | |
| Docetaxel Trihydrate | |
| Docetaxel anhydrous | |
| Erlotinib | |
| Gefitinib | |
| Gemcitabine HCl | |
| Gemcitabine HCI (Alternate process) | |
| Gemcitabine HCl (Alternate process-2) | |
| Irinotecan Hydrochloride Trihydrate | |
| Ibrutinib | |
| Letrozole | |
| Oxaliplatin | |
| Paclitaxel Semi-synthetic | |
| Pemetrexed Diacid | |
| Ribociclib Succinate | |
| Bendamustine Hydrochloride | |
| Alectinib HCl | |
| Plerixafor | |
| Imatinib Mesylate | |
| Neuromuscular Reversal Drug | Sugammadex Sodium |
| Anesthetics | Bupivacaine Hydrochloride |
| Levobupivacaine Hydrochloride | |
| Ropivacaine Hydrochloride Monohydrate | |
| Ropivacaine Hydrochloride Anhydrous | |
| Antibiotic | Chloramphenicol hemisuccinate |
**The buyer / customer should make their independent evaluation of the patent scenario for their respective markets, in respect of the API/formulations bought from Fresenius Kabi Oncology Limited, and they shall be solely and exclusively responsible for all patent related liabilities including any litigation by third party.
Fresenius Kabi Oncology Ltd. do not intend to manufacture any product commercially until there is a valid IP. Listing of product shall not be construed in any way that Fresenius Kabi Oncology has violated any IP laws of the land.
